How does STEP-3 weight loss compare to STEP-1?

STEP-3 produced 16.0% weight loss (semaglutide + IBT) versus STEP-1's 14.9% (semaglutide + monthly counseling). The difference of approximately 1 percentage point suggests IBT adds a modest increment over basic behavioral support when combined with semaglutide.

Did all STEP-3 participants use meal replacements?

Yes. Both arms received a low-calorie diet (1000-1200 kcal/day using meal replacements) for the first 8 weeks, followed by a conventional reduced-calorie diet for the remaining 60 weeks.

What percentage of STEP-3 participants lost more than 20% of body weight?

36.7% of semaglutide-treated participants achieved ≥20% weight loss, compared to 3.7% in the placebo group. This threshold approaches surgical-level outcomes for some patients.

Does STEP-3 apply to patients with type 2 diabetes?

No. STEP-3 excluded patients with type 2 diabetes. The STEP-2 trial tested semaglutide in diabetic populations but used standard counseling rather than IBT. No trial has combined semaglutide 2.4 mg with IBT in a diabetic cohort.

How many counseling sessions did STEP-3 participants receive?

Both arms received 30 individual counseling sessions with registered dietitians over 68 weeks. Sessions were weekly for the first 24 weeks, then biweekly through week 68.

Is the STEP-3 IBT protocol realistic in standard clinical practice?

For most patients, no. Thirty dietitian visits over 68 weeks exceeds typical insurance coverage for behavioral health. Most US plans cap nutrition counseling at 6-12 visits per year, creating access barriers to replicating the trial's behavioral arm.

What happened to weight after semaglutide was stopped?

STEP-3 did not include an off-treatment phase. However, the related STEP-4 trial showed that patients who discontinued semaglutide after 20 weeks regained approximately two-thirds of lost weight by week 68, demonstrating that continued treatment is necessary to maintain weight loss.

Did STEP-3 measure cardiovascular outcomes?

No. STEP-3 was not powered for cardiovascular events. The SELECT trial (2023) later demonstrated cardiovascular benefit of semaglutide 2.4 mg in patients with established cardiovascular disease and overweight/obesity but without diabetes.

What were the most common side effects in STEP-3?

Gastrointestinal events dominated: nausea (53% semaglutide vs 26% placebo), diarrhea (36% vs 22%), vomiting (24% vs 7%), and constipation (24% vs 10%). Most events were mild-to-moderate and occurred during dose escalation.

How does semaglutide 2.4 mg compare to tirzepatide based on STEP-3 data?

Direct comparison is not possible from STEP-3 alone. The SURMOUNT-1 trial of tirzepatide (without IBT) produced 20.9% weight loss at the highest dose. No tirzepatide trial has tested an IBT combination, making head-to-head assessment speculative without a dedicated comparative trial.

What STEP-3 Actually Changes in Clinical Practice

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

| Parameter | Detail | |-----------|--------| | N | 611 (semaglutide 407, placebo 204) | | Intervention | Semaglutide 2.4 mg SC weekly + intensive behavioral therapy (30 counseling sessions) | | Comparator | Placebo SC weekly + identical IBT program | | Duration | 68 weeks (16-week dose escalation + 52 weeks maintenance) | | Primary endpoint | Percent change in body weight from baseline to week 68 | | Key result | −16.0% (sema+IBT) vs −5.7% (placebo+IBT); estimated treatment difference −10.3 percentage points (95% CI, −12.0 to −8.6; P <0.001) |

Why This Trial Exists Separately from STEP-1

The STEP-1 trial tested semaglutide 2.4 mg against monthly lifestyle counseling, representing the minimum behavioral support most clinics deliver. STEP-3 asked a harder question: does semaglutide still add meaningful weight loss when patients already receive the gold-standard behavioral intervention?

This matters because payers and guidelines historically positioned lifestyle modification as the first-line treatment, with pharmacotherapy reserved for "failures." STEP-3 reframes the relationship. The primary publication documents that even patients receiving 30 dietitian-led counseling sessions, a low-calorie diet phase (1000-1200 kcal/day for the first 8 weeks), and structured physical activity targets still lost only 5.7% of body weight with placebo. Adding semaglutide nearly tripled weight loss in that same high-support environment.

Methodology Details That Change Interpretation

The IBT Program Was Not Token

Both arms received an identical 30-session IBT curriculum delivered by registered dietitians. Sessions occurred weekly for the first 24 weeks, then every 2 weeks through week 68. This intensity exceeds what most commercial programs offer and what most insurance plans cover. The initial 8-week low-calorie diet (meal replacements providing 1000-1200 kcal/day) is an aggressive start that many real-world patients never attempt.

Dose Escalation and the Caloric Restriction Overlap

Semaglutide was escalated over 16 weeks to the 2.4 mg maintenance dose. The trial protocol initiated the low-calorie diet phase simultaneously with randomization, meaning patients experienced severe caloric restriction while on sub-therapeutic semaglutide doses. By week 8 (when the low-calorie phase ended), most participants had only reached the 1.0 mg dose. The full pharmacologic appetite suppression from 2.4 mg was operative only after week 16.

This design detail suggests the weight trajectories diverged most sharply after week 16, when semaglutide reached full dose and the caloric restriction phase had already ended. The published weight-loss curves confirm this pattern.

Randomization Was 2:1

The 2:1 allocation (407 semaglutide vs 204 placebo) increases precision for estimating the drug effect but limits the precision of placebo-arm estimates. Dropout was 11.5% in the semaglutide group and 13.7% in the placebo group, relatively balanced for an obesity trial of this duration.

The HealthRX Practice-Change Framework for STEP-3

We evaluate whether a trial should change prescribing through four lenses: magnitude, durability, generalizability, and access friction. For STEP-3:

| Lens | Assessment | |------|-----------| | Magnitude | 16.0% mean weight loss exceeds thresholds for metabolic benefit (5-10%) and approaches bariatric-surgery territory for some patients. 75.3% of semaglutide participants lost ≥10%. | | Durability | Weight remained suppressed at 68 weeks under continued treatment. No plateau reversal was observed, but no off-treatment data exist within this trial. STEP-4 extension data suggest regain after discontinuation. | | Generalizability | Trial excluded type 2 diabetes (separate STEP-2 population). Mean BMI was 38 kg/m². 77% female, 84% White. Results may not extrapolate to post-bariatric, elderly, or metabolically distinct populations. | | Access friction | IBT at STEP-3 intensity requires 30 visits over 68 weeks. Most US insurance plans cap behavioral visits at 6-12 per year. The combination as tested is practically inaccessible to most patients without significant out-of-pocket spending. |

What Actually Changed After Publication

Guideline Updates

The 2022 American Gastroenterological Association guideline cited STEP-3 when recommending pharmacotherapy as an adjunct to (not a replacement for) lifestyle intervention. The Endocrine Society's 2024 updated clinical practice guideline for pharmacologic management of obesity similarly referenced the STEP program when elevating GLP-1 agonists to first-line pharmacotherapy.

The key shift: guidelines no longer recommend sequential "fail lifestyle first, then add drugs." Instead, concurrent initiation is supported when BMI thresholds are met.

FDA Label Implications

The Wegovy prescribing information recommends use "as an adjunct to a reduced calorie diet and increased physical activity." It does not specify IBT intensity. STEP-3 data informed the label language but did not mandate 30-session programs. Clinicians can cite STEP-1 (monthly counseling) or STEP-3 (intensive counseling) depending on what their patients can access.

Prescribing Pattern Shifts

Three practical changes emerged from STEP-3 data:

Combination framing replaced sequencing. Clinics that previously trialed 3-6 months of behavioral intervention before considering medication began initiating both simultaneously.
IBT programs restructured around pharmacotherapy. Programs that historically focused on caloric restriction and behavioral adherence shifted counseling content toward medication management, side-effect coping (particularly nausea during dose escalation), and long-term maintenance planning.
Payer negotiations referenced the data. The 10.3 percentage-point additive benefit of semaglutide over IBT alone gave prior-authorization appeals a concrete number to cite when justifying drug coverage for patients already engaged in behavioral programs.

Results Beyond the Primary Endpoint

| Outcome | Semaglutide + IBT | Placebo + IBT | Difference | |---------|-------------------|---------------|------------| | Mean weight loss (%) | −16.0 | −5.7 | −10.3 pp | | ≥5% weight loss | 86.6% | 47.6% |, | | ≥10% weight loss | 75.3% | 27.0% |, | | ≥15% weight loss | 55.8% | 13.2% |, | | ≥20% weight loss | 36.7% | 3.7% |, | | Waist circumference (cm) | −14.6 | −6.3 | −8.3 | | Systolic BP (mmHg) | −5.6 | −2.8 | −2.8 | | HbA1c (% points) | −0.45 | −0.25 | −0.20 |

Data sourced from Wadden et al., JAMA 2021.

The 36.7% of semaglutide-arm patients achieving ≥20% weight loss is clinically significant because this threshold approaches mean outcomes reported for laparoscopic sleeve gastrectomy in comparable BMI ranges.

Limitations the Authors Acknowledged

The published discussion identified several constraints:

No semaglutide-without-IBT arm. The trial cannot isolate whether IBT adds to semaglutide or semaglutide adds to IBT, only that the combination exceeds IBT alone. Cross-trial comparison with STEP-1 (semaglutide + monthly counseling: −14.9%) suggests IBT adds roughly 1 percentage point, but indirect comparisons carry bias.
Short duration relative to a chronic disease. 68 weeks of follow-up cannot characterize 5- or 10-year outcomes. Weight regain after GLP-1 discontinuation (documented in STEP-4) raises questions about indefinite treatment necessity.
Demographic homogeneity. 84% White, 77% female, mean age 46. Black and Hispanic patients were underrepresented relative to US obesity prevalence patterns.
Industry sponsorship. Novo Nordisk funded the trial and participated in design, data collection, and manuscript review.

What This Means for Patients Who Differ from the Trial Population

Patients with type 2 diabetes: STEP-2 tested semaglutide 2.4 mg in diabetic populations with standard counseling. Weight loss was lower (−9.6%). Whether IBT-intensity counseling would recover the gap seen in STEP-3's non-diabetic cohort remains untested.

Post-bariatric patients: No STEP trial enrolled patients with prior bariatric surgery. Altered GI anatomy may affect semaglutide absorption kinetics. Case series suggest efficacy, but no RCT data exist.

Patients over 65: Mean trial age was 46. Sarcopenic obesity in older adults raises distinct concerns about lean-mass preservation during rapid weight loss. The STEP-3 protocol did not include resistance-training mandates or DEXA-guided monitoring.

Patients unable to access IBT: The practical reality for most patients. STEP-1 data (−14.9% with monthly counseling) suggest that semaglutide delivers the majority of its benefit regardless of behavioral-support intensity. The incremental yield of IBT appears modest (approximately 1 percentage point based on indirect comparison), though the confidence interval around that estimate is wide.

The Practical Takeaway for Prescribers

STEP-3 demonstrated that semaglutide's pharmacologic effect is not redundant with behavioral therapy. Even when patients receive intensive dietary counseling, meal replacements, and structured exercise programming, the drug produces substantial additional weight loss. The reverse is also true but less dramatic: behavioral support beyond basic counseling adds only marginally to the drug's effect.

For clinical decision-making, this means: do not withhold pharmacotherapy because a patient is "already doing well" with behavioral modification, and do not skip behavioral counseling because the drug "does the work." The combination is superior, but if access constraints force a choice, pharmacotherapy delivers the larger independent contribution to weight loss.

Frequently asked questions

›

References

Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403-1413. PubMed
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed
Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. PubMed
Wegovy (semaglutide) prescribing information. Novo Nordisk. Revised 2023. FDA
Grunvald E, Shah R, Hernaez R, et al. AGA Clinical Practice Guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198-1225. PubMed